Retatrutide (LY3437943) — Research Grade | 10mg / 20mg
Retatrutide represents the cutting edge of incretin-based metabolic research. Originally developed by Eli Lilly, it is a synthetic peptide designed as a simultaneous agonist of three key receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and the glucagon receptor. This triple mechanism distinguishes it from earlier generation compounds such as semaglutide (GLP-1 only) and tirzepatide (GLP-1/GIP), making it a compound of significant interest in advanced metabolic and obesity research.
In laboratory research models, retatrutide has been explored for its potential role in appetite regulation, energy expenditure, fat metabolism, hepatic lipid reduction, and glucose homeostasis. Its glucagon receptor activity, absent in prior generation GLP-1 compounds, is of particular research interest for its potential contribution to thermogenesis and energy output.
Each AuroraNX vial is supplied as a white lyophilised powder, sealed under nitrogen, and is stable at room temperature during transit. Upon arrival, store refrigerated at 2–8°C. Reconstitute with bacteriostatic water prior to use.
Specifications
- Sequence: LY3437943
- Purity: ≥99% (HPLC verified, COA available)
- Form: Lyophilised powder
- Vial sizes: 10mg / 20mg
- Storage: Refrigerate at 2–8°C post-reconstitution

